kabutan

Sumitomo Pharma, 69% Increase in Net Income for The Current Fiscal Year

Tue May 13, 2025 1:00 pm JST Earnings

4506 Sumitomo Pharma Co., Ltd. 【IFRS】

Earnings Report

Sumitomo Pharma Co., Ltd. <4506> [TSE Prime] announced its financial results (based on IFRS) in the afternoon session on May 13th (13:00). The consolidated net income/loss for the fiscal year ending March 2025 turned into a profit of 23.6 billion yen (compared to a loss of 314 billion yen in the previous period). For the fiscal year ending March 2026, the consolidated net income is expected to expanded to 69.2% to 40 billion yen.

In the most recent three-month period, from January to March (4Q), the consolidated net income/loss turned to a profit of 2.41 billion yen (compared to a loss of 197 billion yen in the same period last year). The operating profit/loss margin drastically improved from -298.1% in the same period last year to 14.7%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 555,544 -76,979 -47,920 -74,512 -187.6 21 May 15, 2023 IFRS
Mar, 2024 314,558 -354,859 -323,114 -314,969 -792.8 0 May 14, 2024 IFRS
Mar, 2025 398,832 28,804 17,611 23,634 59.5 0 May 13, 2025 IFRS
YoY +26.8% － － － －

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 398,800 28,800 ー 23,600 59.5 0 Apr 28, 2025 IFRS
Mar, 2025 Results 398,832 28,804 17,611 23,634 59.5 0 May 13, 2025 IFRS
Revision Rate +0.0% +0.0% － +0.1% 0.0%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 180,749 -8,179 -32,406 -32,229 -81.1 0 Oct 30, 2024 IFRS
Apr - Sep, 2025 Guidance ー ー ー ー － 0 May 13, 2025 IFRS
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 314,558 -354,859 -323,114 -314,969 -792.8 0 May 14, 2024 IFRS
Mar, 2025 398,832 28,804 17,611 23,634 59.5 0 May 13, 2025 IFRS
Mar, 2026 Guidance 355,000 54,000 ー 40,000 100.7 0 May 13, 2025 IFRS
YoY -11.0% +87.5% － +69.2% +69.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 79,530 -237,114 -217,923 -197,261 -496.5 -298.1 May 14, 2024 IFRS
Apr - Jun, 2024 90,675 -3,105 17,203 15,937 40.1 -3.4 Jul 31, 2024 IFRS
Jul - Sep, 2024 90,074 -5,074 -49,609 -48,166 -121.2 -5.6 Oct 30, 2024 IFRS
Oct - Dec, 2024 112,434 21,405 56,432 53,448 134.5 19.0 Jan 31, 2025 IFRS
Jan - Mar, 2025 105,649 15,578 -6,415 2,415 6.1 14.7 May 13, 2025 IFRS
YoY +32.8% － +97.1% － －

Related Articles